GlobeNewswire: Affimed N.V. Contains the last 10 of 325 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T15:17:46ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/28/2853795/0/en/Affimed-Reports-2023-Financial-Results-and-Operational-Progress.html?f=22&fvtc=4&fvtv=29719Affimed Reports 2023 Financial Results and Operational Progress2024-03-28T10:30:00Z<![CDATA[MANNHEIM, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the year ended December 31, 2023.]]>https://www.globenewswire.com/news-release/2024/03/21/2850061/0/en/Affimed-To-Report-Full-Year-2023-Financial-Results-Corporate-Update-on-March-28-2024.html?f=22&fvtc=4&fvtv=29719Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 20242024-03-21T10:30:00Z<![CDATA[MANNHEIM, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2023 results and corporate update on March 28, 2024. The Company will host a conference call at 8:30 a.m. EDT / 13:30 CET.]]>https://www.globenewswire.com/news-release/2024/03/06/2841214/0/en/Affimed-Announces-1-for-10-Reverse-Stock-Split.html?f=22&fvtc=4&fvtv=29719Affimed Announces 1-for-10 Reverse Stock Split2024-03-06T11:30:00Z<![CDATA[MANNHEIM, Germany, March 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that the Company, with prior approval of the Company’s supervisory board and management board, intends to effect a 1-for-10 reverse stock split of its outstanding common shares, par value €0.01 (“Common Shares”) per share.]]>https://www.globenewswire.com/news-release/2024/01/08/2805843/0/en/Affimed-Provides-Clinical-Response-Update-on-AFM24-102-Trial-in-EGFR-wildtype-Non-Small-Cell-Lung-Cancer.html?f=22&fvtc=4&fvtv=29719Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer2024-01-08T21:05:00Z<![CDATA[MANNHEIM, Germany, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today provided an update on the clinical response data for the ongoing AFM24-102 phase 1/2a study in EGFRwt NSCLC.]]>https://www.globenewswire.com/news-release/2024/01/08/2805395/0/en/Affimed-Announces-Leadership-Change-and-Organizational-Restructuring.html?f=22&fvtc=4&fvtv=29719Affimed Announces Leadership Change and Organizational Restructuring2024-01-08T13:00:00Z<![CDATA[MANNHEIM, Germany, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (the "Company" or "Affimed"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that Dr. Adi Hoess, Chief Executive Officer and member of the Management Board, will step down effective January 15, 2024. Dr. Hoess joined Affimed in October 2010 and has served as its Chief Executive Officer since September 2011.]]>https://www.globenewswire.com/news-release/2024/01/03/2803116/0/en/Affimed-Announces-Sale-of-Wholly-Owned-Subsidiary-AbCheck.html?f=22&fvtc=4&fvtv=29719Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck2024-01-03T11:30:00Z<![CDATA[MANNHEIM, Germany, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it has reached a definitive agreement to sell its wholly-owned subsidiary, AbCheck s.r.o., to Ampersand Biomedicines.]]>https://www.globenewswire.com/news-release/2023/12/11/2793678/0/en/Affimed-Announces-Positive-Data-for-AFM24-in-Combination-with-the-PD-L1-Checkpoint-Inhibitor-Atezolizumab-in-Heavily-Pre-treated-EGFR-Wildtype-Non-Small-Cell-Lung-Cancer-Patients.html?f=22&fvtc=4&fvtv=29719Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients2023-12-11T11:02:00Z<![CDATA[MANNHEIM, Germany, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced interim safety and efficacy data on its innate cell engager (ICE®) AFM24 from the ongoing AFM24-102 combination study with atezolizumab, an anti-PD-L1 checkpoint inhibitor, in patients with advanced EGFR-expressing solid tumors. The data update as of December 6th, 2023, includes 15 patients from the EGFR-wildtype NSCLC cohort with a median of 2 prior lines of therapy. Importantly, all patients were pretreated with and ultimately progressed while on PD-[L]1 targeting therapy.]]>https://www.globenewswire.com/news-release/2023/12/11/2793672/0/en/Affimed-Announces-Updated-Phase-1-2-Data-from-Acimtamig-in-Combination-with-Allogeneic-NK-in-Hodgkin-Lymphoma-Patients-Who-Failed-Prior-Chemotherapy-and-Are-Double-Refractory-to-Br.html?f=22&fvtc=4&fvtv=29719Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)2023-12-11T11:00:00Z<![CDATA[MANNHEIM, Germany, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced updated data on its lead innate cell engager (ICE®) acimtamig. Data from the investigator-initiated trial is being presented today at the American Society of Hematology (ASH) 2023 Annual Meeting by Yago Nieto, M.D., Ph.D., Professor of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center and principal investigator of the study. Affimed will host a webcast following the presentation to review the data and provide a strategic update on acimtamig’s future development.]]>https://www.globenewswire.com/news-release/2023/12/04/2789843/0/en/Affimed-to-Host-Investor-Conference-Call-Highlighting-Clinical-Data-for-Acimtamig-AFM13-and-AFM24.html?f=22&fvtc=4&fvtv=29719Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM242023-12-04T11:30:00Z<![CDATA[MANNHEIM, Germany, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host a conference call on December 11 at 1:30 p.m. PST / 4:30 p.m. EST to review clinical data presented from the combination trial of acimtamig with cord-blood derived NK cells during the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, CA. During the call, the Company will also provide a clinical data update from the AFM24-102 trial.]]>https://www.globenewswire.com/news-release/2023/11/14/2779870/0/en/Affimed-Reports-Third-Quarter-2023-Financial-Results-and-Highlights-Operational-Progress.html?f=22&fvtc=4&fvtv=29719Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress2023-11-14T11:30:00Z<![CDATA[MANNHEIM, Germany, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the third quarter of 2023.]]>